Competing pursuits
AJA has obtained assist (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, Novartis and has consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, Telix exterior the submitted work. CH reported proudly owning inventory in Johnson and Johnson; receiving private charges from Tempus, Genzyme, EMD Sorono, OncLive/MJH Life Sciences, Merck, and grants from Merck, Bausch Well being, Genentech, Bayer, and AstraZeneca exterior the submitted work. TBD reported consulting/advisory relationships with AstraZeneca, Bayer, Janssen, Sanofi. DK reported consulting/Honoraria for Exelixis, Pfizer. MJH life science; Advisory board for Eisai, Exelixis; institutional funding from Genetech, Exelixis; and audio system bureau for Aveo, Jannsen, Astellas. VSK reported consulting or advisory position for AstraZeneca, Janssen, Pfizer, EMD Serono, Seagen, Astellas, Guidepoint, GLG and ExpertConnect; has obtained analysis funding for the establishment from Endocyte/Novartis, Nektar, Gilead, Janssen, Taiho, Merck and Seagen, particular person analysis funding from Eli Lilly and is supported by the Prostate Most cancers Basis. MTS reported being a guide and/or obtained Honoria from Sanofi, AstraZeneca, Janssen, Fibrogen, and Pfizer. He has obtained analysis funding to his establishment from Novartis, Zenith Epigenetics, Eli Lilly, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Hoffmann-La Roche, Tmunity, SignalOne Bio, Epigenetix, Xencor, Incyte and Ambrx, Inc. RRM reported consulting or advisory board for Ambrx, AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Eisai, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus. She has obtained istitutional analysis assist Exelixis, BMS, AstraZeneca, Oncternal, Artera, Tempus. RG has obtained institutional analysis funding from Endocyte/Superior Accelerator Functions, Pfizer, Amgen, Immunomedics, and Xencor exterior the submitted work. MAB reported receiving private charges from Exelixis, Bayer, Bristol Myers Squibb, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Well being, Nektar, EMD Serono, SeaGen, and Sanofi and grants from Merck, Xencor, Bayer, Bristol Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Prescribed drugs, Genome & Firm, AAA, Peloton Therapeutics, and Pfizer exterior the submitted work. AT reported receiving private charges from Genzyme, Exelixis, Seattle Genetics, Deka Biosciences, and Aldi Biosciences and grants from EMD Serono and Aravive exterior the submitted work. PCB reported receiving private charges from AVEO Oncology, Bayer, Pfizer, Caris Life Sciences, AstraZeneca, Myovant, Curio Science, Focused Oncology, Bristol Myers Squibb, MJH Life Sciences, Seagen, and Vaniam Group and grants from EMD Serono exterior the submitted work ASA reported serving as an advisor to AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer. He has beforehand obtained institutional analysis funding from Arcus Biosciences, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Genentech, Merck Sharp & Dohme, Janssen, Mirati Therapeutics, Progenics, Prometheus Laboratories, and Roche. He has additionally obtained journey and lodging from Bristol-Myers Squibb and Merck.
Ethics approval and consent to take part
Not relevant. This was deemed IRB and affected person consent exempt as a retrospective and centrally deidentified examine with a central database.
